MA5-15424

antibody from Invitrogen Antibodies

Targeting: ETV4 E1A-F, E1AF, PEA3

Western blot (Supportive data in Antibodypedia)

ELISA (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15424

Provider

Invitrogen Antibodies

Product name

ETV4 Monoclonal Antibody (1A2G3)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-15424 targets ETV4 in indirect ELISA, WB applications and shows reactivity with Human samples. The MA5-15424 immunogen is purified recombinant fragment of human ETV4 (aa50-109) expressed in E. Coli. MA5-15424 detects ETV4 which has a predicted molecular weight of approximately 54kDa.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

1A2G3

Vial size

100 µL

Concentration

Conc. Not Determined

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

IP(6)-assisted CSN-COP1 competition regulates a CRL4-ETV5 proteolytic checkpoint to safeguard glucose-induced insulin secretion.

Lin H, Yan Y, Luo Y, So WY, Wei X, Zhang X, Yang X, Zhang J, Su Y, Yang X, Zhang B, Zhang K, Jiang N, Chow BKC, Han W, Wang F, Rao F
Nature communications 2021 Apr 28;12(1):2461

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of ETV4 using ETV4 monoclonal antibody (Product # MA5-15424) in HEK293T cells transfected with the pCMV6-ENTRY control (1) and pCMV6-ENTRY ETV4 cDNA (2).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of ETV4 using ETV4 monoclonal antibody (Product # MA5-15424) in K562 cell lysate (1).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 3 Activation of the CRL4 COP1 -ETV5 degradation axis underlies glucose-induced insulin secretion and is constitutively augmented in Csn2 WT/K70E (Het) mice. a Effect of MLN4924 treatment (2 muM, 2 h) on basal and glucose-stimulated insulin secretion by wild-type and Csn2 WT/K70E islets ( n = 6, *** p < 0.001, calculated by two-way ANOVA testing the effect of 2.8 or 16.8 mM glucose in the presence of MLN4924, the other p values were calculated by two-tailed Student's t test). Data are presented as mean +- SEM. b , c Mice serum insulin levels with/without MLN4924 treatment (15 mg/kg, twice weekly for 6 weeks). Insulin levels were measured at the same time of the day to minimize fluctuation. ( n = 6, ** p = 0.001, calculated by two-way repeated measures ANOVA testing genotype x time effect for Het mice). Data are presented as mean +- SEM. c Mice body weight with/without MLN4924 treatment (15 mg/kg, twice weekly for 6 weeks; n = 6, *** p < 0.001, calculated by two-way repeated measures ANOVA testing genotype x time effect for Het mice). Data are presented as mean +- SEM. d Levels of total and neddylated Cullins, COP1, and CRL4 substrates in the pancreas after 6 h fasting to normalize variation in blood glucose levels. e Ex vivo, lentiviral shRNA-based knockdown screening for CRL4 adaptors whose depletion alters islet insulin secretion. Quantified values of insulin secretion were normalize by that of Ctrl islets and presented in Log 2 scale. f Effect of adenovirus-mediated in